Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00470223 | Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma | PHASE3 | ACTIVE NOT_RECRUITING | 318 | — | — | Mar 1, 2007 | Dec 1, 2026 | Jun 8, 2025 | 37 | France |
| Arm | Type | Description |
|---|---|---|
| Chemotherapy + zoledronic acid | EXPERIMENTAL | - |
| chemotherapy | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| cisplatin | DRUG | - |
| doxorubicin hydrochloride | DRUG | - |
| etoposide | DRUG | - |
| ifosfamide | DRUG | - |
| methotrexate | DRUG | - |
| zoledronic acid | DRUG | - |
| conventional surgery | PROCEDURE | - |
Inclusion Criteria * Histologically confirmed high-grade osteosarcoma * Bilirubin ≤ 2 times upper limit of normal * No medical condition that would preclude study treatment * Not pregnant or nursing * Fertile patients must use effective contraception * Shortening fraction ≥ 28% * LVEF ≥ 50% * Glome...